Compremium’s Compartmental Compressibility Monitoring System CPMX1 is the first medical device capable of measuring the compressibility of muscles and tissue in the human body non-invasively and with high precision.

The CPMX1 is intended for real-time and intermittent monitoring of relative muscle compartment compressibility.

This innovative, new device represents a turning point in diagnostics because it enables health care professionals to measure and monitor pressure-related health conditions non-invasively and reliably for the first time.

The CPMX1 provides objective muscle or tissue compressibility values related to trauma, emergencies, or chronic conditions. Data obtained with the help of the Compartmental Compressibility Monitoring System CPMX1 is of high importance and can aid to reduce the number of missed and delayed diagnoses as well as eliminate overtreatment due to uncertainties in the clinical evaluation.

This is a big step forward in clinical practice and enables better care for patients with urgent and unmet medical needs.

“We are extremely proud to receive FDA clearance after an intense two-year development and validation phase for our revolutionary device. In multiple clinical studies, the CPMX1 System has proven to be a precise, reliable diagnostic aid. To develop our platform technology even further, we are currently working with scientific partners, institutions, and reputed hospitals around the world,” says Vincent Baumann, CEO of Compremium Corp.

The CPMX1 System is based on a solid technological development history that saw its predecessor devices being used by NASA in the International Space Station (ISS) to help diagnose and better understand health concerns of astronauts in the weightlessness of space.